Global Gastroenterology Market

Gastroenterology Market Size, Share, Growth Analysis, By Drug Type(Antacids, Laxatives, Antidiarrheal agents, Antiemetics), By Dosage Form(Oral, Parenteral, Other Dosage Forms), By Application(Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease), By Region - Industry Forecast 2024-2031

Report ID: SQSG35I2028 | Region: Global | Published Date: July, 2036
Pages: 165 | Tables: 96 | Figures: 76

Gastroenterology Market News

  • In July 2022, AbbVie announced that they received the approval of RINVOQ® (upadacitinib, 45 mg [induction dosage] and 15 mg and 30 mg [maintenance doses]) from the European Commission (EC), for the treatment of adult patients with moderately to highly active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic drug.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Gastroenterology Market size was valued at USD 48.37 billion in 2019 and is poised to grow from USD 51.37 billion in 2023 to USD 88.35 billion by 2031, growing at a CAGR of 6.21% in the forecast period (2024-2031).

The market for gastrointestinal medicines is moderately fragmented. To increase their market share, the market players have widely used competition sustainability methods such as new product development and regional and distribution channel expansion. Furthermore, a greater emphasis on supply chain management and operational improvement has made it easier for major companies to keep a competitive edge. 'AbbVie Inc.', 'Allergan plc', 'AstraZeneca plc', 'Boehringer Ingelheim International GmbH', 'Eisai Co., Ltd.', 'GlaxoSmithKline plc', 'Johnson & Johnson', 'Novartis International AG', 'Pfizer Inc.', 'Procter & Gamble Co.', 'Salix Pharmaceuticals, Inc.', 'Sanofi S.A.', 'Shire plc', 'Takeda Pharmaceutical Company Limited', 'Valeant Pharmaceuticals International, Inc.', 'Amgen Inc.', 'Aptalis Pharma US, Inc.', 'Danone S.A.', 'Ferring Pharmaceuticals', 'Nestle Health Science'

Rising incidence of gastrointestinal diseases: Globally, the prevalence of gastrointestinal conditions such gallstones, ulcerative colitis, fissure, hemorrhoids, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD) has dramatically grown. The main causes of the rising prevalence of chronic and acute gastrointestinal illnesses are poor diet, a sedentary lifestyle, stress, food sensitivity, and bacterial or viral infections. Numerous drugs, such as antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics, are increasingly in demand to treat various gastrointestinal disorders and prevent subsequent medical consequences related to the diseases. This is driving up the demand for different classes or types of pharmaceuticals to treat gastrointestinal ailments, which is driving up the growth of the market for therapeutics for gastrointestinal diseases.

The demand for developing cutting-edge medicines is being driven by the increase in severe to moderate gastrointestinal disorders, such as ulcerative colitis, Crohn's disease, and other gastrointestinal ailments. In order to expand their product pipeline, pharmaceutical and biotechnology businesses are concentrating on R&D to find and create novel medications for the treatment of gastrointestinal illnesses. The market for gastrointestinal illnesses therapeutics is anticipated to see growth prospects during the forecast period as a result of firms' increasing focus on the development of revolutionary innovative therapies for effectively treating gastrointestinal ailments. During the forecast period, the growing development of gastrointestinal illness medications by regional and international vendors is anticipated to significantly contribute to the growth of the worldwide gastrointestinal disorders therapeutics market.

Based on the region, the North American region currently dominates the gastroenterology market. The market in North America had the biggest share in 2021 and is anticipated to hold that position during the projected period. Technological advancements, an unprecedented change in lifestyle leading to a higher incidence of gastrointestinal diseases, an increase in the number of geriatric and obese people, and rising research and development activities with the presence of key market players are some of the factors that are fueling the market growth in the North American region. Additionally, the government's measures to prevent and treat gastrointestinal disorders are anticipated to propel the market. For instance, UNICEF and WHO's Integrated Action Plan for Diarrhea aims to reduce the number of child deaths that can be prevented due to diarrhea by providing interventions and services to increase awareness and offer access to treatment and preventative measures.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Gastroenterology Market

Product ID: SQSG35I2028